Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: RLMD) | Delayed: 3.27 -0.02 (0.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.29 | 52 Week High | $4.10 | |||
| Open | $3.26 | 52 Week Low | $0.87 | |||
| Day High | $3.34 | P/E | N/A | |||
| Day Low | $3.18 | EPS | $0.00 | |||
| Volume | 1,100,740 | |||||
